Abstract
Purpose of Review
To update the current knowledge concerning sleep complaints and breathing disorders in myotonic dystrophy type 2 (DM2) and to better understand if sleep and breathing symptoms may add a further clinical definition of DM2.
Recent Findings
Although DM2 has been poorly evaluated, the most relevant sleep disorders are sleep-disordered breathing (SDB) (37.5–66.7%) and restless legs syndrome (RLS) (50–60%). Excessive daytime somnolence (EDS) is not consistent with SDB, and a large percentage of patients with sleep complaints (58–69%) report pain. In addition, respiratory dysfunctions are reported in 6 to 15% of DM2 patients, albeit few data are available regarding pulmonary restriction, hypoventilation, and non-invasive ventilation (NIV).
Summary
SDB, RLS, and pain may contribute to sleep fragmentation and EDS in DM2. In addition, few studies report hypoventilation and pulmonary restriction, although there are no studies at all on NIV, except for limited clinical experiences. These findings suggest performing a careful pulmonary examination and NIV when required. Furthermore, sleep studies and respiratory evaluation should be recommended if OSA or respiratory muscle dysfunctions are suspected. A large polysomnographic study should be performed to clarify the link between sleep disorders, pain, and sleep disruption in DM2.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81:358–67.
Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11:891–905.
Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science. 1992;255:1253–5.
Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864–7.
• Wenninger S, Montagnese F, Schoser B. Core clinical phenotypes in myotonic dystrophies. Front Neurol. 2018;9:303 A comprehensive revision of clinical phenotypes of both DM1 and DM2.
LoRusso S, Weiner B, Arnold WD. Myotonic dystrophies: targeting therapies for multisystem disease. Neurotherapeutics. 2018;15:872–84.
•• Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B. Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol. 2017;264:2472–80 A detailed clinical chacterization of a large cohort of DM2 patients investigating the role of age and gender influencing DM2 phenotype.
• Fermin AM, Afzal U, Culebras A. Sleep in neuromuscular diseases. Sleep Med Clin. 2016;11:53–64 A comprehensive review regarding the relationship between sleep disorders and neuromuscular disorders.
Laberge L, Gagnon C, Dauvilliers Y. Daytime sleepiness and myotonic dystrophy. Curr Neurol Neurosci Rep. 2013;13:340.
Bianchi MLE, Losurdo A, Di Blasi C, Santoro M, Masciullo M, Conte G, et al. Prevalence and clinical correlates of sleep disordered breathing in myotonic dystrophy types 1 and 2. Sleep Breath. 2014;18:579–89.
Tieleman AA, Knoop H, van de Logt A-E, Bleijenberg G, van Engelen BGM, Overeem S. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry. 2010;81:963–7.
Romigi A, Albanese M, Placidi F, Izzi F, Liguori C, Marciani MG, et al. Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires. Eur J Neurol. 2014;21:929–34.
Lam EM, Shepard PW, St Louis EK, Dueffert LG, Slocumb N, McCarter SJ, et al. Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology. 2013;81:157–64.
Kohn NN, Faires JS, Rodman T. Unusual manifestations due to involvement of involuntary muscle in dystrophia myotonica. N Engl J Med. 1964;271:1179–83.
Coccagna G, Mantovani M, Parchi C, Mironi F, Lugaresi E. Alveolar hypoventilation and hyperosmnia in myotonic dystrophy. J Neurol Neurosurg Psychiatry. 1975;38:977–84.
Coccagna G, Martinelli P, Lugaresi E. Sleep and alveolar hypoventilation in myotonic dystrophy. Acta Neurol Belg. 1982;82:185–94.
Romigi A, Albanese M, Liguori C, Placidi F, Marciani MG, Massa R. Sleep-wake cycle and daytime sleepiness in the myotonic dystrophies. J Neurodegener Dis. 2013;2013:692026.
Yu H, Laberge L, Jaussent I, Bayard S, Scholtz S, Raoul M, et al. Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study. Sleep. 2011;34:165–70.
Romigi A, Izzi F, Pisani V, Placidi F, Pisani LR, Marciani MG, et al. Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study. Eur J Neurol. 2011;18:1139–45.
Dauvilliers YA, Laberge L. Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. Sleep Med Rev. 2012;16:539–45.
Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43:163–77.
Shepard P, Lam EM, St Louis EK, Dominik J. Sleep disturbances in myotonic dystrophy type 2. Eur Neurol. 2012;68:377–80.
Leonardis L, Blagus R, Dolenc GL. Sleep and breathing disorders in myotonic dystrophy type 2. Acta Neurol Scand. 2015;132:42–8.
Romigi A, Placidi F, Albanese M, Izzi F, Liguori C, Mercuri NB, et al. Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology. 2014;83:572–3.
• Romigi A, Franco V, Placidi F, Liguori C, Rastelli E, Vitrani G, et al. Comparative sleep disturbances in myotonic dystrophy types 1 and 2. Curr Neurol Neurosci Rep. 2018;18:102 The most recent comparative review regading sleep disoders in DM1 and DM2.
Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol. 2014;27:599–606.
Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355:545–6.
Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;68:799–808.
• Meola G, Cardani R. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci. 2017;38:535–46 A clear clinical and genetic chacterization of DM2.
Sansone VA. The dystrophic and nondystrophic myotonias. Continuum (Minneap, Minn). 2016;22:1889–915.
Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord. 2003;13:813–21.
Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet. 2011;19:776–82.
•• Vanacore N, Rastelli E, Antonini G, Bianchi MLE, Botta A, Bucci E, et al. An age-standardized prevalence estimate and a sex and age distribution of myotonic dystrophy types 1 and 2 in the Rome Province, Italy. Neuroepidemiology. 2016;46:191–7 The first age-standardized minimun prevalence and sex and age distribution study of both DM1 and DM2 in a large European general population.
Grigg-Damberger MM, Wagner LK, Brown LK. Sleep hypoventilation in patients with neuromuscular diseases. Sleep Med Clin. 2012;7:667–87.
• Boentert M, Wenninger S, Sansone VA. Respiratory involvement in neuromuscular disorders. Curr Opin Neurol. 2017;30:529–37 A recent review reagarding respiratoty involvement in neuroscular diseases.
•• Poussel M, Thil C, Kaminsky P, Mercy M, Gomez E, Chaouat A, et al. Lack of correlation between the ventilatory response to CO2 and lung function impairment in myotonic dystrophy patients: evidence for a dysregulation at central level. Neuromuscul Disord. 2015;25:403–8 DM1 patients showed reduced ventilatory response to CO2 independent of lung function impairment and respiratory muscle weakness, suggesting a central cause of CO2 insensitivity.
Mathieu J, Allard P, Potvin L, Prévost C, Bégin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology. 1999;52:1658–62.
Poussel M, Kaminsky P, Renaud P, Laroppe J, Pruna L, Chenuel B. Supine changes in lung function correlate with chronic respiratory failure in myotonic dystrophy patients. Respir Physiol Neurobiol. 2014;193:43–51.
•• Sansone VA, Gagnon C. Participants of the 207th ENMC workshop. 207th ENMC workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27-29 June 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25:432–42 A consensus conference regarding chronic respiratory involvement in mytonic dystrophies. The authors reported the sole experience of NIV in DM2.
Pincherle A, Patruno V, Raimondi P, Moretti S, Dominese A, Martinelli-Boneschi F, et al. Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1. Neuromuscul Disord. 2012;22:219–24.
Gagnon C, Heatwole C, Hébert LJ, Hogrel J-Y, Laberge L, Leone M, et al. Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015. J Neuromuscul Dis. 2018;5:523–37.
Bozovic I, Peric S, Pesovic J, Bjelica B, Brkusanin M, Basta I, et al. Myotonic dystrophy type 2 - data from the Serbian registry. J Neuromuscul Dis. 2018;5:461–9.
Bhat S, Sander HW, Grewal RP, Chokroverty S. Sleep disordered breathing and other sleep dysfunction in myotonic dystrophy type 2. Sleep Med. 2012;13:1207–8.
Banach M, Antczak J, Rola R. Association of peripheral neuropathy with sleep-related breathing disorders in myotonic dystrophies. Neuropsychiatr Dis Treat. 2017;13:133–40.
American Academy of Sleep Medicine. International classification of sleep disorders. In: 3rd ed. Darien IL, editor. IL: American Academy of SleepMedicine; 2014; 53.
Laberge L, Gagnon C, Jean S, Mathieu J. Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. J Neurol Neurosurg Psychiatry. 2005;76:1403–5.
Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–95.
George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol. 2004;61:1938–42.
Silvestri G, Bianchi MLE, Losurdo A, Della MG. Author response. Neurology. 2014;83:572–3.
Laberge L, Bégin P, Dauvilliers Y, Beaudry M, Laforte M, Jean S, et al. A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry. 2009;80:642–6.
Ciafaloni E, Mignot E, Sansone V, Hilbert JE, Lin L, Lin X, et al. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology. 2008;70:226–30.
•• Bonanni E, Carnicelli L, Crapanzano D, Maestri M, Simoncini C, Baldanzi S, et al. Disruption of sleep-wake continuum in myotonic dystrophy type 1: beyond conventional sleep staging. Neuromuscul Disord. 2018;28:414–21 A polysomnographic study regarding DM1 patients and cyclic alternating pattern analysis. The authors confirmed REM sleep dysregulation, sleep fragmentation, and nonREM alterations as expressed by slower delta power decline.
Chokroverty S, Bhat S, Rosen D, Farheen A. REM behavior disorder in myotonic dystrophy type 2. Neurology. 2012;78:2004.
Huang J, Zhang J, Lam SP, Li SX, Ho CKW, Lam V, et al. Amelioration of obstructive sleep apnea in REM sleep behavior disorder: implications for the neuromuscular control of OSA. Sleep. 2011;34:909–15.
Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep. 1997;20:757–88.
Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM. 2008;101:49–60.
• Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, et al. Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). Neurology. 2015;85:2136–46 A large survey regading DM2 burden as perceived by DM2 patients.
• Rakocevic Stojanovic V, Peric S, Paunic T, Pesovic J, Vujnic M, Peric M, et al. Quality of life in patients with myotonic dystrophy type 2. J Neurol Sci. 2016;365:158–61 Evaluation of the quality of life of DM2 by disease-specific scales, demonstrating that the most severe DM2 had similar low QoL as in DM1.
Tieleman AA, den Broeder AA, van de Logt AE, van Engelen BGM. Strong association between myotonic dystrophy type 2 and autoimmune diseases. J Neurol Neurosurg Psychiatry. 2009;80:1293–5.
Rohleder N, Aringer M, Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci. 2012;1261:88–96.
Romigi A, Pierantozzi M, Izzi F, Desiato MT, Liguori C, Marchi A, et al. Restless legs syndrome and poliomyelitis: new evidences of an old observation? Front Neurol. 2015;6:23.
•• Romigi A, Pierantozzi M, Placidi F, Evangelista E, Albanese M, Liguori C, et al. Restless legs syndrome and post polio syndrome: a case-control study. Eur J Neurol. 2015;22:472–8 The first case-control study showing high prevalence of restless legs syndrome in post-polio syndrome.
Suokas KI, Haanpää M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve. 2012;45:70–4.
•• van Vliet J, Tieleman AA, Verrips A, Timmerman H, van Dongen RTM, van Engelen BGM, et al. Qualitative and quantitative aspects of pain in patients with myotonic dystrophy type 2. J Pain. 2018;19:920–30 Pain as a key clinical feature of DM2, as demonstrated by widespreadness of hyperalgesia in DM2.
Peric M, Peric S, Rapajic N, Dobricic V, Savic-Pavicevic D, Nesic I, et al. Multidimensional aspects of pain in myotonic dystrophies. Acta Myol. 2015;34:126–32.
Tieleman AA, Jenks KM, Kalkman JS, Borm G, van Engelen BGM. High disease impact of myotonic dystrophy type 2 on physical and mental functioning. J Neurol. 2011;258:1820–6.
Moshourab R, Palada V, Grunwald S, Grieben U, Lewin GR, Spuler S. A molecular signature of myalgia in myotonic dystrophy 2. EBioMedicine. 2016;7:205–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Andrea Romigi reports other from EISAI, personal fees from SANDOZ, personal fees from Fidia Farmaceutici, outside the submitted work. Giuseppe Vitrani received a personal fee from Fidia Farmaceutici outside the submitted work. Enrica Bonanni, Marco Caccamo, Diego Centonze, Michelangelo Maestri, Carmine Nicoletta, Alessandro Sanduzzi, and Gabriele Siciliano each declare no potential conflicts of interest.
Human and Animal Rights
The article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Sleep
Rights and permissions
About this article
Cite this article
Romigi, A., Maestri, M., Nicoletta, C. et al. Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2. Curr Neurol Neurosci Rep 19, 9 (2019). https://doi.org/10.1007/s11910-019-0924-0
Published:
DOI: https://doi.org/10.1007/s11910-019-0924-0